Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Lebanon has been experiencing steady growth in recent years.
Customer preferences: Lebanese customers are increasingly seeking out Anti-Rheumatic Drugs due to the high prevalence of rheumatoid arthritis and other related conditions in the country. In addition, there is a growing awareness among patients about the importance of early diagnosis and treatment of these conditions, which has led to increased demand for these drugs.
Trends in the market: One of the key trends in the Anti-Rheumatic Drugs market in Lebanon is the shift towards biologic drugs. These drugs have been shown to be more effective in treating rheumatoid arthritis and other related conditions, and as a result, they are becoming increasingly popular among patients. In addition, there has been a growing trend towards the use of combination therapies, which involve the use of multiple drugs to treat these conditions.
Local special circumstances: One of the unique factors that is driving the growth of the Anti-Rheumatic Drugs market in Lebanon is the high prevalence of rheumatoid arthritis and related conditions in the country. This has led to a high demand for these drugs, and as a result, many pharmaceutical companies have been targeting the Lebanese market with their products. In addition, there is a well-established healthcare system in the country, which has made it easier for patients to access these drugs.
Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in Lebanon is also being driven by a number of underlying macroeconomic factors. For example, the country has a relatively high per capita income, which means that patients are able to afford these drugs. In addition, there is a well-developed healthcare system in the country, which has made it easier for patients to access these drugs. Finally, there is a growing awareness among healthcare providers about the importance of early diagnosis and treatment of rheumatoid arthritis and related conditions, which has led to increased demand for these drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
